WHAT CLAIMED IS:

1. A crystalline form B of Compound 2:



2

characterized by an X-ray powder diffractogram (XRPD) pattern comprising one or more peaks at 8.16, 13.23 and 13.90 (± 0.2° 2θ).

2. The crystalline form B of claim 1, wherein the XRPD pattern further comprises one or more peaks at 4.94, 11.83, 14.97, 18.54 and 26.24 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 9.89, 19.74 and 20.92 (± 0.2° 2θ).

3. The crystalline form B of claim 1 or 2, characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
4.94	13.23	18.54	22.71
8.16	13.90	19.74	25.35
9.89	14.97	20.92	26.24
11.83	16.29	21.63	28.55

, or characterized by an XRPD pattern substantially as shown in Figure 5A.

4. The crystalline form B of any of claims 1-3, characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with a peak temperature of about 151.1°C, or characterized by a DSC thermogram substantially as shown in Figure 5B.

5. The crystalline form B of any of claims 1-4, wherein the crystalline form B is an anhydrate.

6. A crystalline form C of Compound 2, characterized by an XRPD pattern comprising one or more peaks at 5.06, 10.09 and 20.24 (± 0.2° 2θ).

7. The crystalline form C of claim 6, wherein the XRPD pattern further comprises one or more peaks at 15.15, 16.18 and 16.75 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 7.99, 8.37, 11.71, 12.22, 12.87, 13.60 and 14.04 (± 0.2° 2θ).

8. The crystalline form C of claim 6 or 7, characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
5.06	12.22	16.18	25.89
7.99	12.87	16.75	26.47
8.37	13.60	19.43	30.56
10.09	14.04	20.24	35.80
11.71	15.15	20.96	

, or characterized by an XRPD pattern substantially as shown in Figure 6A.

9. The crystalline form C of any of claims 6-8, characterized by a DSC thermogram having an endotherm with a peak temperature of about 149.0°C, or characterized by a DSC thermogram substantially as shown in Figure 6B.

10. The crystalline form C of any of claims 6-9, wherein the crystalline form C is an anhydrate.

11. A crystalline form D of Compound 2, characterized by an XRPD pattern comprising one or more peaks at 5.03, 12.98, 15.91 and 21.58 (± 0.2° 2θ).

12. The crystalline form D of claim 11, wherein the XRPD pattern further comprises one or more peaks at 5.90, 9.21, 20.47 and 26.08 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 11.76, 15.04, 22.38 and 24.47 (± 0.2° 2θ).

13. The crystalline form D of claim 11 or 12, characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
5.03	11.76	15.91	22.38
5.90	12.98	20.47	24.47
9.21	15.04	21.58	26.08

, or characterized by an XRPD pattern substantially as shown in Figure 7.

14. The crystalline form D of any of claims 11-13, wherein the crystalline form D is a hydrate.

15. A crystalline form E of Compound 2, characterized by an XRPD pattern comprising one or more peaks at 10.12, 11.97, 13.73 and 18.89 (± 0.2° 2θ).

16. The crystalline form E of claim 15, wherein the XRPD pattern further comprises one or more peaks at 5.06, 8.14, 13.02 and 14.19 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 14.87, 21.30, 22.33 and 26.23 (±

0.2° 2θ).

17. The crystalline form E of claim 15 or 16, characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
5.06	16.32	22.33	27.18
8.14	18.00	23.01	27.68
10.12	18.89	23.78	28.57
11.97	19.36	24.23	29.51
13.02	19.89	25.07	31.40
13.73	20.31	25.40	32.47
14.19	20.67	26.23	36.45
14.87	21.30	26.74	39.05

, or characterized by an XRPD pattern substantially as shown in Figure 12.

18. The crystalline form E of any of claims 15-17, wherein the crystalline form E is an anhydrate.

19. A crystalline form F of Compound 2, characterized by an XRPD pattern comprising one or two peaks at 15.50 and 21.23 (± 0.2° 2θ).

20. The crystalline form F of claim 19, wherein the XRPD pattern further comprises one or two peaks at 12.12 and 20.21 (± 0.2° 2θ).

21. The crystalline form F of claim 19 or 20, characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
12.12	15.50	20.21	21.23

, or characterized by an XRPD pattern substantially as shown in Figure 14A.

22. The crystalline form F of any of claims 19-21, characterized by a DSC thermogram having endotherms with peak temperatures of about 111.2°C and/or about 149.8°C; and/or characterized by a DSC thermogram having an exothermal with a peak temperature of about 118.9°C; preferably characterized by a DSC thermogram substantially as shown in Figure 14B.

23. The crystalline form F of any of claims 19-22, wherein the crystalline form F is a hydrate.

24. A crystalline form G of Compound 2, characterized by an XRPD pattern comprising one or more peaks at 9.67, 11.60, 12.90 and 14.43 (± 0.2° 2θ).

25. The crystalline form G of claim 24, wherein the XRPD pattern further comprises one or more peaks at 8.16, 13.69, 13.91, 16.15, 18.51, 18.93 and 20.47 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 4.95, 11.83, 13.22 and 19.84. (± 0.2° 2θ).

26. The crystalline form G of claim 24 or 25, characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
4.95	13.69	19.84	28.60
8.16	13.91	20.47	29.94
9.67	14.43	22.70	35.09
11.60	14.84	25.28	35.93
11.83	16.15	26.24	
12.90	18.51	26.81	
13.22	18.93	27.59	

,
or characterized by an XRPD pattern substantially as shown in Figure 15A.

27. The crystalline form G of any of claims 24-26, characterized by a DSC thermogram having endotherms with peak temperatures of about 72.4°C and/or about 83.1°C; or characterized by a DSC thermogram substantially as shown in Figure 15B.

28. The crystalline form G of any of claims 24-27, wherein the crystalline form G is a DMSO solvate.

29. A salt of Compound 2:



2

,

wherein the salt of Compound 2 is selected from sodium salt, potassium salt, arginine salt, magnesium salt or tromethamine salt of compound 2.

30. The salt of compound 2 of claim 29, wherein the salt of Compound 2 is in a crystalline form A of sodium salt of Compound 2 characterized by an XRPD pattern comprising one or more peaks at 4.09, 4.62 and 14.21 (± 0.2° 2θ) ; and/or the XRPD pattern further comprises one or two peaks at 16.43 and 17.72 (± 0.2° 2θ).

31. The salt of Compound 2 of claim 30, wherein the crystalline form A of sodium salt is characterized by an XRPD pattern comprising one or more peaks selected from

the group consisting of:

°2θ	°2θ	°2θ
4.09	14.21	17.72
4.62	16.43	

,
or characterized by an XRPD pattern substantially as shown in Figure 24A.

32. The salt of Compound 2 of claim 30 or 31, wherein the crystalline form A of sodium salt is characterized by a DSC thermogram having endotherms with peak temperatures of about 163.5°C and/or about 204.0°C; and/or characterized by a DSC thermogram having an exothermal with a peak temperature of about 166.5°C; preferably characterized by a DSC thermogram substantially as shown in Figure 24B.

33. The salt of Compound 2 of claim 29, wherein the salt of Compound 2 is in a crystalline form C of potassium salt of Compound 2 characterized by an XRPD pattern comprising one or more peaks at 12.91, 14.96 and 21.23 (± 0.2° 2θ).

34. The salt of Compound 2 of claim 33, wherein the XRPD pattern further comprises one or more peaks at 14.12, 20.68, 25.17 and 26.46 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 3.92, 18.08, 22.48, 24.70 and 25.81 (± 0.2° 2θ).

35. The salt of Compound 2 of claim 33 or 34, wherein the crystalline form C of potassium salt is characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
3.92	14.96	20.68	25.17
6.90	16.05	21.23	25.81
7.79	16.83	22.48	26.46
12.91	18.08	23.28	30.84
14.12	19.11	24.70	

,
or characterized by an XRPD pattern substantially as shown in Figure 26A.

36. The salt of Compound 2 of any of claims 33-35, wherein the crystalline form C of potassium salt is characterized by a DSC thermogram having endotherms with peak temperatures of about 108.1°C, about 140.2°C and/or about 161.3°C, or characterized by a DSC thermogram substantially as shown in Figure 26B.

37. The salt of Compound 2 of claim 29, wherein the salt of Compound 2 is in a crystalline form A of arginine salt of Compound 2 characterized by an XRPD pattern comprising one or more peaks at 12.93, 13.43, 18.21 and 19.49 (± 0.2° 2θ).

38. The salt of Compound 2 of claim 37, wherein the XRPD pattern further comprises one or more peaks at 10.91, 15.83, 19.14, 20.93, 21.15 and 22.02 (± 0.2° 2θ); and/or the XRPD pattern further comprises one or more peaks at 11.34, 19.84, 20.45, 25.63 and 26.15 (± 0.2° 2θ).

39. The salt of Compound 2 of claim 37 or 38, wherein the crystalline form A of arginine salt is characterized by an XRPD pattern comprising one or more peaks selected from the group consisting of:

°2θ	°2θ	°2θ	°2θ
7.25	16.94	21.15	27.24
10.91	18.21	22.02	27.81
11.34	19.14	23.46	29.67
12.93	19.49	24.10	30.90
13.43	19.84	25.22	33.07
14.57	20.45	25.63	
15.83	20.93	26.15	

, or characterized by an XRPD pattern substantially as shown in Figure 28A.

40. The salt of Compound 2 of any of claims 37-39, wherein the crystalline form A of arginine salt is characterized by a DSC thermogram having an endotherm with a peak temperature of about 195.2°C or characterized by a DSC thermogram substantially as shown in Figure 28B.

41. The salt of Compound 2 of claim 29, where the salt of Compound 2 is in a crystalline form A of potassium salt of Compound 2 characterized by an XRPD pattern substantially as shown in the upper curve of Figure 19A.

42. The salt of Compound 2 of claim 41, wherein the crystalline form A of potassium salt is characterized by a DSC thermogram having endotherms with peak temperatures of about 91.1°C, about 135.8°C and/or about 147.7°C, or characterized by a DSC thermogram substantially as shown in Figure 19B.

43. The salt of Compound 2 of claim 29, wherein the salt of Compound 2 is in a crystalline form B of potassium salt of Compound 2 characterized by an XRPD pattern substantially as shown in the lower curve of Figure 19A.

44. The salt of Compound 2 of claim 29, wherein the salt of Compound 2 is in a crystalline form A of magnesium salt of Compound 2 characterized by an XRPD pattern substantially as shown in Figure 21A.

45. The salt of Compound 2 of claim 44, wherein the crystalline form A of magnesium salt is characterized by a DSC thermogram having endotherms with peak temperatures of about 90.7°C, about 114.9°C, about 134.0°C and/or about 154.2°C,

or characterized by a DSC thermogram substantially as shown in Figure 21B.

46. The salt of Compound 2 of claim 29, wherein the salt of Compound 2 is in crystalline form A of tromethamine salt of Compound 2 characterized by an XRPD pattern substantially as shown in Figure 22A.

47. The salt of Compound 2 of claim 46, wherein the crystalline form A of tromethamine salt is characterized by a DSC thermogram having endotherms with peak temperatures of about 71.8°C, about 76.6°C, about 113.9°C and/or about 213.1°C, or characterized by a DSC thermogram substantially as shown in Figure 22B.

48. The crystalline form of any of claims 1-28 or the salt of any of claims 29-47 is in substantially pure form, optionally the crystalline form or the salt has a purity of at least 90wt%.

49. A pharmaceutical composition comprising Compound 2 and a pharmaceutically acceptable excipient, wherein Compound 2 is in a crystalline form selected from the group consisting of: the crystalline form B of any of claims 1-5, the crystalline form C of any of claims 6-10, the crystalline form D of any of claims 11-14, the crystalline form E of any of claims 15-18, the crystalline form F of any of claims 19-23, and the crystalline form G of any of claims 24-28.

50. The pharmaceutical composition of claim 49, wherein at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, 99.5%, 99.9% or 99.99% of Compound 2 is in crystalline form B, crystalline form C, crystalline form D, crystalline form E, crystalline form F, or crystalline form G.

51. A pharmaceutical composition comprising a salt of Compound 2 of any of claims 29-47and a pharmaceutically acceptable excipient.

52. The pharmaceutical composition of claim 51, wherein at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, 99.5%, 99.9% or 99.99% of the salt of Compound 2 is in the crystalline form A of sodium salt, the crystalline form C of potassium salt, the crystalline form A of arginine salt, the crystalline form A of potassium salt, the crystalline form B of potassium salt, the crystalline form A of magnesium salt, or the crystalline form A of tromethamine salt.

53. Use of the crystalline form of Compound 2 or the salt of Compound 2 of any one of claims 1-48 or the pharmaceutical composition of any of claims 49-52 in the manufacture of a medicament for the treatment and/or prophylaxis of diseases which are modulated by PPARα and/or PPARγ agonists.

54. The use of claim 53, wherein the disease is diabetes, non-insulin dependent

diabetes mellitus, elevated blood pressure, dyslipidemia, atherosclerotic diseases, metabolic syndrome, or diabetic nephropathy; or the disease is renal injury.

55. The use of claim 54, wherein the renal injury is caused by ureteral obstruction or unilateral ureteral obstruction.